


Prior Authorization Review Panel

CHC-MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review.
Policies submitted without this form will not be considered for review.

Plan: PA Health & Wellness	Submission Date: 02/01/2020
Policy Number: PA.CP.PHAR.463	Effective Date: 01/2021 Revision Date: 01/2021
Policy Name: Satralizumab-mwge (Enspryng)	
<p>Type of Submission – <u>Check all that apply:</u></p> <ul style="list-style-type: none"> <input checked="" type="checkbox"/> New Policy <input type="checkbox"/> Revised Policy* <input type="checkbox"/> Annual Review - No Revisions <input type="checkbox"/> Statewide PDL - <i>Select this box when submitting policies for Statewide PDL implementation and when submitting policies for drug classes included on the Statewide PDL.</i> 	
<p>*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document.</p> <p>Please provide any changes or clarifying information for the policy below:</p> 	
<p>Name of Authorized Individual (Please type or print):</p> <p>Auren Weinberg, MD</p>	<p>Signature of Authorized Individual:</p> 

Clinical Policy: Satralizumab-mwge (Enspryng)

Reference Number: PA.CP.PHAR.463

Effective Date: 01/2021

Last Review Date: 01/2021

[Coding Implications](#)
[Revision Log](#)

Description

Satralizumab-mwge (Enspryng™) is an anti-interleukin-6 receptor antagonist.

FDA Approved Indication(s)

Enspryng is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with PA Health & Wellness® that Enspryng is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Neuromyelitis Optica Spectrum Disorder (must meet all):

1. Diagnosis of NMOSD;
2. Prescribed by or in consultation with a neurologist
3. Age \geq 18 years;
4. Member has positive serologic test for anti-AQP4 antibodies;
5. Member has experienced at least one relapse within the previous 12 months;
6. Member has a history of at least two relapses during the previous 24 months;
7. Baseline expanded disability status scale (EDSS) score of \leq 6.5;
8. Failure of rituximab at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
**Prior authorization may be required for rituximab*
9. At the time of request, member does not have active hepatitis B infection (positive results for hepatitis B surface antigen and anti-hepatitis B virus tests) or active or untreated latent tuberculosis;
10. Enspryng is not prescribed concurrently with rituximab, Soliris®, or Uplizna™;
11. Dose does not exceed 120 mg at weeks 0, 2, and 4, and every 4 weeks thereafter.

Approval duration: 6 months

B. Other diagnoses/indications

1. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PACP.PMN.53

II. Continued Therapy

A. Neuromyelitis Optica Spectrum Disorder (must meet all):

1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.LTSS.PHAR.01) applies;
 2. Member is responding positively to therapy – including but not limited to improvement or stabilization in any of the following parameters:
 - a. Frequency of relapse;
 - b. EDSS;
 - c. Visual acuity;
 3. Enspryng is not prescribed concurrently with rituximab, Soliris, or Uplizna;
 4. If request is for a dose increase, new dose does not exceed 120 mg every 4 weeks.
- Approval duration: 6 months**

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via PA Health & Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.LTSS.PHAR.01) applies.
Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – PA.CP.PMN.53

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

AQP-4: aquaporin-4
 EDSS: expanded disability status scale
 FDA: Food and Drug Administration
 NMO/DM: neuromyelitis optica spectrum disorder

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Rituxan [®] /Ruxience [™] / Truxima [®] (rituximab)*	375 mg/m ² per week for 4 weeks as induction, followed by 375 mg/m ² biweekly every 6 to 12 months	See regimen

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

**Off-label*

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): known hypersensitivity to satralizumab or any of the inactive ingredients, active hepatitis B infection, active or untreated latent tuberculosis

- Boxed warning(s): none reported

Appendix D: General Information

- AQP-4-IgG-seropositive status is confirmed with the use of commercially available cell-binding kit assay (Euroimmun).

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
NMOSD	120 mg SC at weeks 0, 2, 4, and every 4 weeks thereafter	See regimen

VI. Product Availability

Solution for injection in a single-dose prefilled syringe: 120 mg/mL

VII. References

1. Enspryng Prescribing Information. South San Francisco, CA: Genentech, Inc.; August 2020. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761149s000lbl.pdf. Accessed August 24, 2020.
2. Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. *N Engl J Med.* 2019; 381: 2114-2124.
3. Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. *Lancet Neurol.* 2020; 19(5): 402-412.
4. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. *European Journal of Neurology.* 2010; 17: 1019–1032.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
TBD	Injection, satralizumab-mwge, 120 mg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created	01/2021	